Endovascular brachytherapy of transjugular intrahepatic portosystemic shunt.

Abstract

PURPOSE:

To evaluate the technical feasibility and efficacy of endovascular brachytherapy with Iridium-192 in the prevention of restenosis caused by neointimal hyperplasia of transjugular intrahepatic portosystemic shunt (TIPS).

MATERIALS AND METHODS:

The endovascular brachytherapy with high dose rate automatic afterloading system was performed in six patients with recurrent of stenosis of TIPS. We used a single dose fraction of 12 Gy delivered at 3 millimeter (mm) from the source axis to the stenotic vessel segment in five patients with spiral Z-stent, and 15 Gy at 5 mm in one patient with Wallstent.

RESULTS:

Follow-up time ranged from 148 to 639 days. In one patient, restenosis occurred in the treated vessel segment, diagnosed 71 days after endovascular brachytherapy by doppler ultrasound. All other patients were, during the follow-up time, without restenosis in the irradiated vessel segment. Radiation-associated side effects were not observed.

CONCLUSIONS:

Endovascular brachytherapy of TIPS is technically feasible and may be done as a part of the percutaneous revision of the shunt. This pilot study may be the largest experience of treating TIPS restenosis in humans to date. For definitive conclusions, a lot of studies are needed.

• Authors: J Dvorák, P Hůlek, J Raupach, T Vanásek, J Petera, A Krajina, J Vanásek, Z Zoul, K Odrázka, M Lojík, J Masková, V Safka, P Vodnanský, J Fridrich
• Journal: Cardiovascular radiation medicine (Cardiovasc Radiat Med) 2000 Jan-Mar Vol. 2 Issue 1 Pg. 3-6 ISSN: 1522-1865 [Print] United States
• PMID: 11229059 (Publication Type: Journal Article)

Chemical References

• Iridium Radioisotopes

Topics

• Adult
• Brachytherapy (methods)
• Constriction, Pathologic (radiotherapy)
• Feasibility Studies
• Female
• Humans
• Iridium Radioisotopes (therapeutic use)
• Male
• Pilot Projects
• Portasystemic Shunt, Transjugular Intrahepatic
• Recurrence
• Stents